CT Screening in the Age of Health Care Reform

With the conclusion of the National Lung Screening Trial (NLST) and release of new NCCN guidelines pointing toward increased application of Low Dose CT Screening for high risk lung cancer patients, the question looms: What will this look like in the rapidly evolving healthcare environment?

Please join us for an interactive discussion on potential clinical, practice andeconomic ramifications of changes in LDCT screening practices. Panel memberswill provide insight on emerging recommendations, establishment of ascreening program, and anticipated coverage changes.

This symposium aims to present and discuss:

• Evolution of guidelines following the NLST trial

• Suggested practices for establishing a local screening program

• Changes in reimbursement and potential impact of Health Care Reform

  • Covidien.com
  •  Request Information

Presenters

Robert C. McDonald, MD

Robert C. McDonald, MD President, Aledo Consulting Inc.
Voluntary Clinical Associate Professor of Medicine Indiana University School of Medicine
View Full Profile

Frank C. Detterbeck, MD, FACS, FCCP

Frank C. Detterbeck, MD, FACS, FCCP Chief, Thoracic Surgery
Professor of Surgery (Section of Thoracic Surgery)
Surgical Director, Thoracic Oncology
Associate Director, Clinical Affairs at Yale Cancer Center
View Full Profile

Michael S. Mulligan, MD

Michael S. Mulligan, MD Professor, Cardiothoracic Surgery, Univ of Wash School of Medicine
Director, Lung Transplant Program and the Advanced Lung Disease Surgery Program, University of Washington Medical Center
Director, Minimally Invasive Thoracic Surgery Program, UWMC
View Full Profile